Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
05
2019
revised:
09
07
2019
accepted:
21
08
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
23
10
2019
Statut:
epublish
Résumé
Lysophosphatidic acid (LPA) is a bioactive phospholipid with mitogenic and growth factor-like activities affecting cell invasion, cancer progression, and resistance. It is produced mainly by autotaxin and acts on six G-protein-coupled receptors, LPAR1-6. LPA has recently been implicated as a growth factor present in ascites of ovarian cancer patients. However, mitogenic pathways stimulated by LPA via its receptors may involve any novel, thus far uncharacterized, signaling pathway(s). Here we show that three LPA receptors are involved in tumor progression by activation of both the AKT and ERK signaling pathways. CRISPR-edited LPAR2 and LPAR3 knockouts have opposing effects on ERK activation, whereas LPAR6 is involved in the activation of AKT, affecting cell migration and invasion. Our study identifies specific molecular machinery triggered by LPA and its receptors that modulates tumor cells and can serve as therapeutic target in this malignancy.
Identifiants
pubmed: 31636669
doi: 10.1155/2019/7547469
pmc: PMC6766155
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7547469Informations de copyright
Copyright © 2019 Hadil Onallah et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ann Oncol. 1998 Apr;9(4):437-42
pubmed: 9636836
BMC Cancer. 2016 Nov 4;16(1):846
pubmed: 27809800
Gynecol Oncol. 2007 Mar;104(3):714-20
pubmed: 17204312
Cell Signal. 2018 Apr;44:138-147
pubmed: 29329782
Cancers (Basel). 2018 Jul 09;10(7):null
pubmed: 29987226
J Biol Chem. 2005 Mar 18;280(11):10564-71
pubmed: 15653692
Oncol Lett. 2014 May;7(5):1581-1585
pubmed: 24765180
J Lipid Res. 2014 Jul;55(7):1192-214
pubmed: 24643338
Exp Mol Med. 2008 Dec 31;40(6):607-16
pubmed: 19116446
PLoS One. 2009;4(5):e5583
pubmed: 19440550
Cancers (Basel). 2018 Mar 15;10(3):null
pubmed: 29543710
PLoS One. 2010 Dec 30;5(12):e15940
pubmed: 21209852
Virchows Arch. 2018 Oct;473(4):463-470
pubmed: 30032361
Croat Med J. 2008 Apr;49(2):175-81
pubmed: 18461672
Cell Signal. 2015 Sep;27(9):1751-62
pubmed: 26027517
Nat Rev Cancer. 2013 Apr;13(4):273-82
pubmed: 23426401
Biol Cell. 2013 Aug;105(8):317-33
pubmed: 23611148
Exp Mol Med. 2008 Aug 31;40(4):445-52
pubmed: 18779657
Genes Cancer. 2012 Sep;3(9-10):578-91
pubmed: 23486563
BMC Cancer. 2014 Jun 13;14:432
pubmed: 24928086
Cancer Lett. 2003 Mar 31;192(2):161-9
pubmed: 12668280
Mol Diagn Ther. 2019 Feb;23(1):127-138
pubmed: 30694446
Stem Cells. 2016 Mar;34(3):551-64
pubmed: 26800320
J Thorac Dis. 2014 May;6(5):483-90
pubmed: 24822107
JAMA. 1998 Aug 26;280(8):719-23
pubmed: 9728644
Eur J Biochem. 2004 Apr;271(8):1557-65
pubmed: 15066181
Cancer Res. 2018 Apr 15;78(8):1923-1934
pubmed: 29386184
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
Life Sci. 2007 Apr 10;80(18):1641-9
pubmed: 17367815
Cancer Lett. 2015 Jan 28;356(2 Pt B):382-91
pubmed: 25451317
J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42
pubmed: 19001604
Biochem J. 2006 Mar 1;394(Pt 2):495-500
pubmed: 16356167